Impact of Body Mass Index on Platelet Aggregation After Administration of a High Loading Dose of 600 mg of Clopidogrel Before Percutaneous Coronary Intervention

American Journal of Cardiology

Volumn 100, Issue 2, 2007, Pages 203-205

  Sibbing, Dirk ^a   von Beckerath, Olga ^a   Schömig, Albert ^a   Kastrati, Adnan ^a   von Beckerath, Nicolas ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; COUMARIN DERIVATIVE; FIBRINOGEN RECEPTOR ANTAGONIST;

ARTICLE; BODY MASS; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG MEGADOSE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; OBESITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; SINGLE DRUG DOSE; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT;

ADENOSINE DIPHOSPHATE; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BODY MASS INDEX; FEMALE; HUMANS; MALE; MULTIVARIATE ANALYSIS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE;

EID: 34447274446     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.02.081     Document Type: Article

References (19)

1. Kastrati A., Mehilli J., Neumann F.J., Dotzer F., ten Berg J., Bollwein H., Graf I., Ibrahim M., Pache J., Seyfarth M., et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 295 (2006) 1531-1538
2. Mehilli J., Kastrati A., Schühlen H., Dibra A., Dotzer F., von Beckerath N., Bollwein H., Pache J., Dirschinger J., Berger P.P., and Schömig A. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation 110 (2004) 3627-3635
3. Kastrati A., Mehilli J., Schühlen H., Dirschinger J., Dotzer F., ten Berg J.M., Neumann F.J., Bollwein H., Volmer C., Gawaz M., Berger P.B., and Schömig A. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 350 (2004) 232-238
4. Willett W.C., Dietz W.H., and Colditz G.A. Guidelines for healthy weight. N Engl J Med 341 (1999) 427-434
5. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., Barrera Ramirez C., Sabate M., Fernandez C., Hernandez-Antolin R., Escaned J., Alfonso F., and Macaya C. Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted?. J Invasive Cardiol 16 (2004) 169-174
6. Patel M.R., and Peterson E.D. Clopidogrel dosing in overweight patients: does one size fit all?. J Invasive Cardiol 16 (2004) 175-176
7. Takaya J., Iwamoto Y., Higashino H., Kino M., Kobayashi T., and Kobayashi Y. Altered intracellular calcium and phorbol 12,13-dibutyrate binding to intact platelets in young obese subjects. J Lab Clin Med 129 (1997) 245-250
8. Kotlyar M., and Carson S.W. Effects of obesity on the cytochrome P450 enzyme system. Int J Clin Pharmacol Ther 37 (1999) 8-19
9. Alfonso F., and Angiolillo D.J. Platelet function assessment to predict outcomes after coronary interventions: hype or hope?. J Am Coll Cardiol 48 (2006) 1751-1754
10. O'Donoghue M., and Wiviott S.D. Clopidogrel response variability and future therapies: clopidogrel: does one size fit all?. Circulation 114 suppl (2006) e600-e606
11. Hochholzer W., Trenk D., Bestehorn H.P., Fischer B., Valina C.M., Ferenc M., Gick M., Caputo A., Buttner H.J., and Neumann F.J. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 48 (2006) 1742-1750
12. Angiolillo D.J., Bernardo E., Ramirez C., Costa M.A., Sabate M., Jimenez-Quevedo P., Hernandez R., Moreno R., Escaned J., Alfonso F., et al. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol 48 (2006) 298-304
13. Feher G., Koltai K., Alkonyi B., Papp E., Keszthelyi Z., Kesmarky G., and Toth K. Clopidogrel resistance: role of body mass and concomitant medications. Int J Cardiol (2006)
14. Garrison R.J., and Castelli W.P. Weight and thirty-year mortality of men in the Framingham Study. Ann Intern Med 103 (1985) 1006-1009
15. Gruberg L., Mercado N., Milo S., Boersma E., Disco C., van Es G.A., Lemos P.A., Ben Tzvi M., Wijns W., Unger F., Beyar R., and Serruys P.W. Impact of body mass index on the outcome of patients with multivessel disease randomized to either coronary artery bypass grafting or stenting in the ARTS trial: The obesity paradox II?. Am J Cardiol 95 (2005) 439-444
16. Gruberg L., Weissman N.J., Waksman R., Fuchs S., Deible R., Pinnow E.E., Ahmed L.M., Kent K.M., Pichard A.D., Suddath W.O., Satler L.F., and Lindsay Jr. J. The impact of obesity on the short-term and long-term outcomes after percutaneous coronary intervention: the obesity paradox?. J Am Coll Cardiol 39 (2002) 578-584
17. Kelly R.V., Hsu A., Topol E., and Steinhubl S. The influence of body mass index on outcomes and the benefit of antiplatelet therapy following percutaneous coronary intervention. J Invasive Cardiol 18 (2006) 115-119
18. Powell B.D., Lennon R.J., Lerman A., Bell M.R., Berger P.B., Higano S.T., Holmes Jr. D.R., and Rihal C.S. Association of body mass index with outcome after percutaneous coronary intervention. Am J Cardiol 91 (2003) 472-476
19. von Beckerath N., Taubert D., Pogatsa-Murray G., Schömig E., Kastrati A., and Schömig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 112 (2005) 2946-2950